Sintilimab (approved)

DRUG3 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., West China Hospital, Second Affiliated Hospital, Zhejiang University, School of Medicine

Conditions

Advanced or Metastatic NSCLCExtensive Disease Small Cell Lung CancerExtensive Stage Lung Small Cell CancerExtensive-Stage Small-Cell Lung CancerExtensive-stage Small Cell Lung Cancer (ES-SCLC)Hepatocellular Carcinoma (HCC)

Phase 1

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

CompletedNCT04177290

Innovent Biologics (Suzhou) Co. Ltd.Advanced or Metastatic NSCLC

Start: 2020-04-02End: 2022-09-04Updated: 2023-02-27

Phase 2

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

RecruitingNCT06664996

West China HospitalHepatocellular Carcinoma (HCC)

Start: 2024-10-15End: 2026-10-31Target: 33Updated: 2024-10-30

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

RecruitingNCT07061535

Second Affiliated Hospital, Zhejiang University, School of MedicineExtensive Disease Small Cell Lung Cancer, Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer +1

Start: 2025-07-30End: 2027-08-01Target: 40Updated: 2026-09-15